TCL Archive Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says August 19, 1994
TCL Archive NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions November 7, 1980
TCL Archive FDA Committee Okays High Dose Methotrexate, Mitxantrone In ANL; reverse Breast Cancer Vote December 11, 1987
TCL Archive Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said. October 14, 2005
